secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2022-03-17T23:59:59+00:00
Accession:  0001701541-22-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics reports FY2021 net loss $125.6M; cash $209.8M, runway into 2024
--------------------------------------------------------------------------------

- Net loss FY2021 $125.6M vs $67.3M YoY; Q4 loss $25.9M vs $22.6M.
- Cash $209.8M at Dec 31, 2021 (down from $315.1M); sufficient to fund operations into 2024.
- R&D spend $96.8M in 2021 (vs $48.2M); G&A $30.0M (vs $21.4M).
- FDA allowed IND for BDTX-1535; Phase 1 study initiated for GBM and NSCLC with CNS metastases.
- Appointed Elizabeth Montgomery as Chief People Officer, bringing nearly 20 years HR experience in life sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000006/0001701541-22-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154122000006/bdtx-20220317.htm
  HTML page:      https://secwatch.observer/filing/0001701541-22-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer